Compare DAO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | PVLA |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2019 | 2013 |
| Metric | DAO | PVLA |
|---|---|---|
| Price | $14.79 | $155.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $171.87 |
| AVG Volume (30 Days) | 69.2K | ★ 155.9K |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,810,000.00 |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $14.60 | $104,350.18 |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $8.38 | $52.82 |
| 52 Week High | $18.94 | $161.38 |
| Indicator | DAO | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 54.15 |
| Support Level | $15.59 | $135.68 |
| Resistance Level | $18.79 | $160.07 |
| Average True Range (ATR) | 1.20 | 7.65 |
| MACD | -0.32 | -0.15 |
| Stochastic Oscillator | 28.05 | 76.54 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.